Sponsorship of Education

This page lists 205 references in the Main Healthy Skepticism Library relevant to sponsorship of education by vested interests.

Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.


HSL6832
Vere-Jones E.
Private sector nurse training set to grow.
Nurs Times 2006 Aug 29-Sep

HSL6446
Steinman MA, Bero LA, Chren MM, Landefeld CS
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
Annals of Internal Medicine 2006 Aug 15;145(4):284-293
http://annals.org/cgi/content/abstract/145/4/284

HSL6493
Henney JE.
Safeguarding patient welfare: who's in charge?
Ann Intern Med 2006 Aug 15;145(4):305-7
http://www.annals.org/cgi/content/full/145/4/305

HSL6321
Burton B.
Drug industry told to disclose details of doctors' events
BMJ 2006 Aug 5;333(7562):278
http://bmj.bmjjournals.com/cgi/content/extract/333/7562/278-b

HSL6138
Moynihan R.
Roche defends buying lavish meals for doctors at Sydney's restaurants
BMJ 2006 Jul 22;333(7560):169
http://bmj.bmjjournals.com/cgi/content/short/333/7560/169?etoc%3e

HSL5719
Godllee F.
What price integrity?
BMJ 2006;332 (17 June), 2006 Jun 17;332
http://bmj.bmjjournals.com/cgi/content/short/332/7555/0-f?etoc

HSL5725
Tanne J.
End pharma influence on CME, says AMA journal.
BMJ 2006 Jun 17;332(7555):1410
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1410?etoc

HSL5611
Fugh-berman A, Batt S.
'This may sting a bit': cutting CME’s ties to pharma
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):412-415
http://www.ama-assn.org/ama1/pub/upload/mm/384/oped1_16260.pdf

HSL5822
Kopelow M.
Independence in continuing medical education
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):416-419
http://www.ama-assn.org/ama/pub/category/16261.html

HSL6210
Shiwani MH.
Quest of prescribing practice in Pakistan.
J Pak Med Assoc 2006 May 01;56(5):249-50

HSL5032
Hilliard T, Chambers T.
The relationship between paediatricians and commerce.
Paediatr Respir Rev 2006 Mar;7(1):54-9
http://linkinghub.elsevier.com/retrieve/pii/S1526-0542(05)00086-2

HSL6645
DeSilets LD.
Commercial support for professional development.
J Contin Educ Nurs 2006 Mar-Apr 01;37(2):52-3

HSL5593
Somberg JC.
Pharmaceutical companies and medical therapeutics education.
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3159&uid=16645422&db=PubMed&url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00045391-200603000-00001 Am J Ther 2006 Mar-Apr;13(2):93

HSL6339
Lazarus A.
Pharmaceutical policy issues for medical schools.
Psychiatr Serv 2006 Feb 01;57(2):167
http://ps.psychiatryonline.org/cgi/content/full/57/2/167

HSL5377
Murphy MT.
Is continuing education morphing into dental infomercials?
Dent Today 2006 Feb;25(2):12

HSL5274
Romano M.
Fighting graft--it's academic. Medical centers must embrace conflict rules: critics.
Mod Healthc 2006 Jan 30;36(5):8-10

HSL5674
Lazarus A.
The role of the pharmaceutical industry in medical education in psychiatry.
Acad Psychiatry 2006 Jan-Feb 01;30(1):40-4
http://ap.psychiatryonline.org/cgi/content/full/30/1/40

HSL5675
Jibson MD.
Medical education and the pharmaceutical industry: managing an uneasy alliance.
Acad Psychiatry 2006 Jan-Feb 01;30(1):36-9
http://ap.psychiatryonline.org/cgi/content/full/30/1/36

HSL4035
Huang F, Et AL.
The Association of Pharmaceutical Company Promotional Spending With Resident Physician Prescribing Behavior
Academic Psychiatry 2005 Dec 1(29):500-501
http://ap.psychiatryonline.org/cgi/content/full/29/5/500

HSL5043
Marlow B.
A hypertensive snow bird.
CMAJ 2005 Nov 22;173(11):1357-8
http://www.cmaj.ca/cgi/content/full/173/11/1357-b

HSL5758
Huang FY, Weiss DS, Fenimore PG, Fleming AM, Haller E, Lichtmacher JE, Eisendrath SJ.
The association of pharmaceutical company promotional spending with resident physician prescribing behavior.
Acad Psychiatry 2005 Nov-Dec 01;29(5):500-1
http://ap.psychiatryonline.org/cgi/content/full/29/5/500

HSL5262
Komesaroff PA.
Ethical issues in the relationships with industry: an ongoing challenge. New Guidelines open for public comment.
J Paediatr Child Health 2005 Nov;41(11):558-60
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1754.2005.00719.x

HSL5254
Mahowald MW, Cramer Bornemann MA.
What? Influenced by industry? Not me!
Sleep Med. 2005 Sep 01;6(5):389-90
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=16099216&db=pubmed&url=http://linkinghub.elsevier.com/retrieve/pii/S1389-9457(05)00109-7

HSL2732
Sharfstein SS.
Big Pharma and American Psychiatry: The Good, the Bad, and the Ugly.
Psychiatric News 2005 Aug 19;40(16):3
http://pn.psychiatryonline.org/cgi/content/full/40/16/3

HSL4173
Hotvedt R.
Drug companies and continuing education.
Tidsskr Nor Laegeforen 2005 Aug 11;125(15):2043
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1237547

HSL4200
Engelhardt K.
[The medical-industrial complex: an ethical challenge]
Dtsch Med Wochenschr. 2005 Jul 29;130(30):1778-80
http://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-871895

HSL5074
Chimonas S, Rothman DJ.
New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
Health Aff (Millwood) 2005 Jul-Aug;24(4):949-60
http://www.healthaffairs.org/

HSL1916
Rowland C.
Doctors fight over drug firm influence: Some in hypertension society hit fees paid to members for talks
The Boston Globe 2005 Jun 16

HSL2134
Dubovsky SL.
Who is teaching psychopharmacology? Who should be teaching psychopharmacology?
Academic Psychiatry 29:155-161, June 2005 2005 Jun 01;29:155-161
http://ap.psychiatryonline.org/cgi/content/full/29/2/155

HSL1864
Kowalczyk L.
Psychiatry funding questioned: Drug firms aid Mass. General
The Boston Globe 2005 May 14

HSL2206
Rieger HJ.
[Sponsoring of physicians in private practice]
Z Arztl Fortbild Qualitatssich. 2005 Apr;99(2):161-4

HSL4210
Macias W, Lewis LS, Smith TL.
Health-related message boards/chat rooms on the Web: discussion content and implications for pharmaceutical sponsorships.
J Health Commun 2005 Apr-May;10(3):209-23
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16036729&db=pubmed&url=http://journalsonline.tandf.co.uk/Index/10.1080/10810730590934235

HSL4262
Amidon GL.
Collaborative research training.
Mol Pharm 2005 Mar-Apr 01;2(2):97
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3001&uid=15804183&db=pubmed&url=http://dx.doi.org/10.1021/mp0580807

HSL5880
Industry sponsored meetings and events are favored by physicians
Product Management Today 2005 Mar 1;6

HSL2130
Oldani MJ.
Pharma PR or medical education?
Hastings Cent Rep 2005 Mar-Apr;35(2):6-7

HSL2131
Rentmeester CA.
Pharma PR or medical education?
Hastings Cent Rep 2005 Mar-Apr;35(2):6

HSL2132
Roselin JM.
Pharma PR or medical education?
Hastings Cent Rep 2005 Mar-Apr;35(2):5-6

HSL2133
Sweeney HA.
Pharma PR or medical education?
Hastings Cent Rep 2005 Mar-Apr;35(2):4

HSL1220
Lexchin J, Cassels A.
Does the C in CME stand for "Continuing" or "Commercial"?
CMAJ 2005 Jan 18;172(2):160-2
http://www.cmaj.ca/cgi/content/full/172/2/160-a

HSL1347
Wazana A, Granich A, Primeau F, Bhanji NH, Jalbert M.
Using the literature in developing McGill's guidelines for interactions between residents and the pharmaceutical industry.
Acad Med 2004 Nov;79(11):1033-40
http://www.academicmedicine.org/cgi/content/full/79/11/1033

HSL2817
Grup d'Etica Societat Catalana de Medicina Familiar i Comunitaria.
[Ethics in drug industry relations.
Opinions poll of family physicians in Catalonia]Aten Primaria 2004 Jun 15;34(1):6-12
http://db.doyma.es/cgi-bin/wdbcgi.exe/doyma/mrevista.pubmed_full?inctrl=05ZI0105&rev=27&vol=34&num=1&pag=6

HSL249
Hutchinson MS.
Pharmaceutical companies and medical students: a student's view.
Med J Aust 2004 Apr 19;180(8):414
http://www.mja.com.au/public/issues/180_08_190404/hut10183_fm.html

HSL5926
What's wrong with CME? (editorial).
CMAJ 2004 Mar 16;170(6):917
http://www.cmaj.ca/cgi/reprint/170/6/917

HSL1331
Zoorob R, Larzelere M.
Gifts to physicians from the pharmaceutical and medical manufacturing industry: what every physician should know.
J La State Med Soc 2004 Jan-Feb;156(1):28-32

HSL2151
Keim S, Perina DG; CORD Board of Directors.
Council of Emergency Medicine Residency Directors position on interactions between emergency medicine residencies and the pharmaceutical industry.
Acad Emerg Med 2004 Jan;11(1):78
http://www.aemj.org/cgi/content/full/11/1/78

HSL2152
Keim SM, Mays MZ, Grant D.
Interactions between emergency medicine programs and the pharmaceutical industry.
Acad Emerg Med 2004 Jan;11(1):19-26
http://www.aemj.org/cgi/content/full/11/1/19

HSL2696
Hemminki E, Karttunen T, Hovi SL, Karro H.
The drug industry and medical practice--the case of menopausal hormone therapy in Estonia.
Soc Sci Med 2004 Jan;58(1):89-97
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-48TM3V5-2&_coverDate=01%2F31%2F2004&_alid=307376484&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=be686b45176e3a6cf270c9e1dedc43b1

HSL4242
Tengilimoglu D, Kisa A, Ekiyor A.
The pharmaceutical sales rep/physician relationship in Turkey: ethical issues in an international context.
Health Mark Q 2004;22(1):21-39

HSL2227
Rutledge P, Crookes D, McKinstry B, Maxwell SR.
Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey.
Pharmacoepidemiol Drug Saf. 2003 Dec 01;12(8):663-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14762982&query_hl=3

HSL4276
Brett AS, Burr W, Moloo J.
Are gifts from pharmaceutical companies ethically problematic? A survey of physicians
Archives of Internal Medicine 2003 Oct 13;163(18):2213-2218
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14557219

HSL2137
Romano M.
Too friendly? Teaching hospitals revisit ties to pharmaceutical firms
Mod Healthc. 2003 Jul 14;33(28):17 2003 Jul 14;33(28):17

HSL2102
Wilson FS.
Continuing medical education: ethical collaboration between sponsor and industry.
Clin Orthop Relat Res 2003 Jul(412):33-7

HSL1447
Drack G, Kuhn HP, Haller U; Committee for Quality Preservation of the Swiss Society of Gynaecology and Obstetrics.
[Is continuing medical education under suspicion of corruption? Contribution to the discussion by the Committee for Quality Preservation of the Swiss Society of Gynaecology and Obstetrics]
Gynakol Geburtshilfliche Rundsch 2003 Apr;43(2):111-7
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=GGR43111

HSL2138
Koch DD.
Industry support for physician education.
J Cataract Refract Surg 2003 Mar;29(3):419
http://linkinghub.elsevier.com/retrieve/pii/S0886335003001056

HSL2136
Chen P; Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, NY, USA.
Education or promotion?: Industry-sponsored continuing medical education (CME) as a center for the core/commercial speech debate
Food Drug Law J. 2003;58(3):473-509

HSL2139
Hensley S.
When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Wall St J (East Ed) 2002 Dec 4;:A1,

HSL2165
Katz HP, Goldfinger SE, Fletcher SW.
Academia-industry collaboration in continuing medical education: description of two approaches.
J Contin Educ Health Prof 2002 Win;22(1):43-54

HSL2904
Bennett J, Collins J.
The relationship between physicians and the biomedical industries: advice from the Royal College of Physicians.
Clin Med 2002 Jul-Aug;2(4):320-2
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12195858

HSL2896
Brody H.
A matter of influence: Changing times call for changing policies on the prescence of drug company reps in residency programs
Health Affairs (Millwood). 2002 Mar-Apr;21(2):232-234
http://www.healthaffairs.org/freecontent/s28.htm

HSL2157
Wolfe SM.
The destruction of medicine by market forces: teaching acquiescence or resistance and change?
Acad Med 2002 Jan;77(1):5-7
http://www.academicmedicine.org/cgi/content/full/77/1/5

HSL2853
Jedrey CM, Chaurette KA, Winn LB.
Pharmaceutical company-sponsored disease management programs.
Manag Care Q 2002 Win;10(1):56-60
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12476660http://

HSL2166
Eliasson G, Hakansson J.
[Keep medical education independent! It should not be a scene of drug industry marketing]
Lakartidningen. 2001 Sep 26;98(39):4168-9

HSL2637
McCarthy M.
Drug firm support of American Medical Association ethics effort draws fire.
Lancet 2001 Sep 8;358(9284):821
http://linkinghub.elsevier.com/retrieve/pii/S0140673601060214

HSL2170
Relman AS.
Separating continuing medical education from pharmaceutical marketing.
JAMA 2001 Apr 18;285(15):2009-12
http://jama.ama-assn.org/cgi/content/full/285/15/2009

HSL2169
Sluzki CE.
Drug-company influence on medical education in the U.S
Am J Orthopsychiatry. 2001 Apr;71(2):148-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11347356&query_hl=7

HSL2171
Johnson RG.
Physician education and the pharmaceutical industry.
Chest 2001 Apr;119(4):995-6
http://www.chestjournal.org/cgi/content/full/119/4/995

HSL2763
Franklin , A .
Pharmaceutical companies and CME
OMR 2001 Apr;68(4):10

HSL2380
Dieperink ME, Drogemuller L.
Industry-sponsored grand rounds and prescribing behavior.
JAMA 2001 Mar 21;285(11):1443-4
http://jama.ama-assn.org/cgi/content/full/285/11/1443

HSL2742
Weber W.
Sponsored continuing medical education under scrutiny in Europe
Lancet 2001 Feb 10;357:452

HSL2741
Lal A.
Pharmaceutical drug promotion: how it is being practiced in India?
J Assoc Physicians India 2001 Feb;49:266-73

HSL2135
Okoro EO, Davies AE.
Sponsorship of educational programmes in Nigerian medical and pharmacy schools by pharmaceutical companies: possible risk implication for public health.
Ethics Med 2001 Spr;17(1):52-60

HSL2173
Potdar RD.
Educating ourselves.
Indian Pediatr 2000 Nov;37(11):1287-8
http://www.indianpediatrics.net/nov2000/nov-1287-1288.htm

HSL2993
Sullivan P.
Freebies to MDs targeted as drug industry starts publicizing CME fines
Canadian Medical Association Journal 2000 Sep 19;163(6):749

HSL2175
Drug-company influence on medical education in USA
Lancet 2000 Sep 2;356(9232):781
http://linkinghub.elsevier.com/retrieve/pii/S0140673600026453

HSL2998
Sams WM, Freedberg IM.
The dermatology-industry interface: defining the boundaries.
J Am Acad Dermatol 2000 Sep;43(3):550-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10954674

HSL3047
McCarthy , M .
Medical-education companies come under fire in USA
Lancet 2000 Aug 5;356:494

HSL2174
Mehta PN.
Drugmakers and continuing medical education.
Indian Pediatr 2000 Jun;37(6):626-30

HSL2989
Tenery RM Jr.
Interactions between physicians and the health care technology industry.
JAMA 2000 Jan 19;283(3):391-3
http://jama.ama-assn.org/cgi/content/full/283/3/391

HSL2177
Eckardt VF.
[Promoting research and graduate education by the pharmaceutical industry--scientific progress or marketing strategy?]
Z Gastroenterol. 1999 Jul;Suppl 2:19-27

HSL2140
Razack S, Arbour L, Hutcheon R.
Proposed model for interaction between residents and residency training programs, and pharmaceutical industry.
Ann R Coll Physicians Surg Can 1999 Mar;32(2):93-6

HSL5278
Phatak A.
The pharmaceutical industry and the medical profession.
Issues Med Ethics 1998 Oct-Dec;6(4):131-2

HSL720
Guyatt G.
Determining an ethical stance: Pharmaceutical industry involvement and family medicine residency training
Can Fam Physician 1997 Nov 01;43:1898-900

HSL3133
Katsanis , Prevel L, Olivanti , Christina C.
A review of patient education in promotional activities. Sponsored by the Canadian pharmaceutical industry: a descriptive study
1997 Oct 4
http://www.fadmin.unb.ca/asb/paper42.htm

HSL761
Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P.
Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario.
CMAJ 1996 Nov 1;155(9):1243-

HSL799
Dean M.
Guidelines for CME need revamping.
Can Fam Physician 1996 Jul;42:1295-7

HSL789
Gutkin C, Handfield-jones R.
Guidelines for CME need revamping
Can Fam Physician 1996;42:1296-1297

HSL791
Gilbert D, Chetley A.
New trends in drug promotion
Consumer Policy Review 1996;63(5):162-167

HSL3096
European Public Health Alliance
Commercial sponsorship and NGOs
European Public Health Alliance 1996

HSL1714
Bickell NA.
Drug companies and continuing medical education.
J Gen Intern Med 1995 Jul;10(7):392-4

HSL839
La Puma J, Stocking CB, Rhoades WD, Darling CM, Ferner RE, Neuberger J, VandenBurg M, Dews I, Tobias JS.
Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patients
BMJ 1995 Jun 24;310:1660-1661
http://www.bmj.com/cgi/content/full/310/6995/1660

HSL857
Colby WD.
Guidelines for interaction with the pharmaceutical industry.
CMAJ 1995 Apr 1;152(7):1040-2

HSL828
Rapoport D.
Physicians and the pharmaceutical industry: under the influence?
CMAJ 1995 Jan 1;152(1):15

HSL813
Williams PA, Cockerill R, Lowy FH.
The physician as prescriber: relations between knowledge about prescription drugs, encounters with patients and the pharmaceutical industry, and prescription volume
Health and Canadian Society 1995;3:135-166

HSL827
Rapoport D.
Under the influence of the pharmaceutical industry? Kick the habit.
CMAJ 1995;152:1043

HSL851
Eldridge A.
Sponsorship and the RMI Code of Practice
N Z Med J 1995;108:279

HSL2689
Chren MM, Landefeld CS.
Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.
JAMA 1994 Mar 2;271(9):684-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed

HSL5790
Sheldeon TA, Smith GD.
Consensus conferences as drug promotion
Lancet 1993;341:499

HSL5147
Ethics case study: should drug makers support continuing medical education
American College of Physicians Observer 1993;13(6):1,12-13

HSL5151
Sponsored symposia: science or veiled promotion?
WHO Drug Information 1993;7:26-27

HSL5177
Davis , P .
The cost of CME: who pays?
Canadian Journal of CME 1993;5(9):1-2

HSL5534
Houle G.
CME—where are we going?
Canadian Journal of CME 1993;5(1):1

HSL5537
Huston P.
Doctors want more industry-sponsored meetings
Medical Marketing & Media 1993;28(3):48-50, 52-53

HSL6067
Harrison V
An overview of current guidelines for commercial support of continuing medical education
Journal of Continuing Education in the Health Professions 1993;13:68-76

HSL6068
Van HARRISON, Stross JK.
Requirements for speakers at “promotional” educational activities versus independent CME activities
Academic Medicine 1993;83:841-842

HSL5141
U.S. Food and Drug Administration
Draft policy statement on industry-supported scientific and educational activities
Fed Regist. 1992 Nov 29;57(229):56412-56414.

HSL4974
Jones DC.
Pricing and promotion come under scrutiny
Scrip Magazine 1992 Jun(5):16-18
www.pjbpubs.co.uk/scrip/scrhome.html

HSL4801
Camerlain M.
Three cheers for CME
Canadian Medical Association Journal 1992;146:1153

HSL4822
Freedman M.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146:329

HSL4865
Morris LA, Griffin JP.
The evolving role of FDA in prescription drug promotion
Journal of Drug Issues 1992;22:245-256

HSL4866
Mossinghoff GJ.
Pharmaceutical manufacturers and self-regulation of drug advertising and promotion
Journal of Drug Issues 1992;22:235-243

HSL4913
Swanson RW.
Three cheers for CME?
Canadian Medical Association Journal 1992;146:1519

HSL4936
Wivell MK, O’fallon DA.
Drug overpromotion: when is a warning not a warning?
Trial 1992;28(11):20-27

HSL4938
Woolley RJ.
Pharmaceutical promotion
New England Journal of Medicine 1992;327:1687

HSL2191
Busby J.
Ties that bind? The web of CME and medical industry profit
Tex Med. 1991 Aug;87(8):38-46

HSL4647
Chepesiuk R.
CE sponsorship
Drug Merchandising 1991;72(6):7

HSL4663
Harvey K, Mansfield P.
Drug promotion: the critical approach
Australian Prescriber 1991;14(1):34-35

HSL4667
Hoffman JR.
A knotty ethical dilemma
Emergency Medicine News 1991;13(5):2, 14-15

HSL4707
Skolnick AA.
FDA issues draft 'concept paper' on drug company funding of CME
JAMA 1991;266(21):2947-2948

HSL4717
Webber J.
Wine and cheese and CE: guidelines needed for industry sponsorship
Drug Merchandising 1991;72(4):33

HSL2192
Hayes TM, Allery LA, Harding KG, Owen PA.
Continuing education for general practice and the role of the pharmaceutical industry.
Br J Gen Pract 1990 Dec;40(341):510-2

HSL2195
Caplan RM.
CME ethics, continued.
Iowa Med 1990 Mar;80(3):135

HSL4510
Berube B.
The subtle sell: an overview
Canadian Pharmaceutical Journal 1990;123:397-398

HSL4520
Canavan B.
Forging the alliance: CME’s relationship with industry
Journal of Continuing Education in the Health Professions 1990;10:123-128

HSL4521
Chetley A.
A healthy business? World health and the pharmaceutical industry
Zed Books 1990
http://www.amazon.com/Healthy-Business-Health-Pharmaceutical-Industry/dp/0862327350/ref=sr_1_1/102-1249992-1219339?ie=UTF8&s=books&qid=1174978013&sr=1-1

HSL4553
McSherry J.
Medifacts tapes and advertising
Canadian Family Physician 1990;36:850

HSL4555
Morris LA, Banks DB.
New issues in drug advertising and labeling: the five advertising end-runs
Drug Information Journal 1990;24:639-646

HSL4560
Noble RC.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990;113:408

HSL4562
Odenbach E.
Collaboration with commercial interests in continuing medical education
Journal of Continuing Education in the Health Professions 1990;10:293-301

HSL4574
Roeg N.
The other drug trade
Adbusters 1990;1(4):80-87
www.adbusters.org/adbusters/

HSL4585
Shickman MD.
CME’s relationship with industry
Journal of Continuing Education in the Health Professions 1990;10:189-190

HSL4601
Van HR, Mazmanian PE, Osborne CE.
Commercial support for CME courses sponsored by medical schools
Journal of Continuing Education in the Health Professions 1990;10:197-210

HSL4411
Franaszek JB.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989;18:909

HSL4454
Squires BP.
Continuing medical education: coming of age
Canadian Medical Association Journal 1989;140:491

HSL4497
The basis of medical school cooperation with industry in the production of accredited continuing medical education
Journal of Continuing Education in the Health Professions 1989;10:373-375

HSL4026
Musher DM.
Pharmaceutical company-sponsored symposia and medical ethics.
Am J Med 1988 Oct;85(4):596

HSL4009
Kaufman JL.
Profligate medical marketing.
N Engl J Med 1988 Aug 25;319(8):522

HSL4093
Fisher DA.
The golden age of CME is yet to come [2nd of 3 letters]
JAMA 1988 May 6;259(17):2545

HSL4094
Madigan HS.
The golden age of CME is yet to come [1st of 3 letters]
JAMA 1988 May 6;259(17):2544-2545

HSL4095
Manning PR, Petit DW.
The golden age of CME is yet to come [reply]
JAMA 1988 May 6;259(17):2545-2546

HSL4096
Scarpinato L, Govaker D.
The golden age of CME is yet to come [3rd of 3 letters]
JAMA 1988 May 6;259(17):2545

HSL4088
Healthcare communications and pharmaceutical promotion
Health Horizons 1988 May(4):16-17

HSL4011
Krass M.
New code for drug makers tightens rules on drug samples, research.
CMAJ 1988 Apr 1;138(7):646

HSL2197
[No authors listed]
"A matter of influence": graduate medical education and commercial sponsorship.
N Engl J Med. 1988 Jan 7;318(1):52-4 1988 Jan 7;318(1):52-4

HSL2198
Bowman MA, Pearle DL.
Changes in drug prescribing patterns related to commercial company funding of continuing medical education.
J Contin Educ Health Prof 1988;8(1):13-20

HSL3997
Frishman W.
Pharmaceutical company-sponsored symposia and medical ethics
American Journal of Medicine 1988;85:597

HSL3998
Goldfinger S.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL4005
Holloway WJ.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:New England Journal of Medicin

HSL4012
Kunin CM.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL4017
Lexchin J.
Pharmaceutical promotion in New Zealand.
Community Health Stud 1988;12(3):264-72

HSL4021
McGregor M.
Pharmaceutical “generosity” and the medical profession
Annals of the Royal College of Physicians and Surgeons of Canada 1988;21:289

HSL4060
Relman AS.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53-54

HSL4063
Rosenblatt RA.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:52-53

HSL4072
Tan M.
Dying for drugs: pill power and politics in the Philippines
1988

HSL4074
Tuthill JE.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL4124
Bass M.
Biased Medifacts tape: comment
Canadian Family Physician 1988;35:2219

HSL3873
Crook D.
Drug promotion.
N Z Med J 1987 Nov 25;100(836):725

HSL3772
Carter IE.
Canadian Psychiatric Association guidelines in relating to the pharmaceutical industry.
Can J Psychiatry 1987 Aug;32(6):476-86
http://www.cpa-apc.org/Publications/Position_Papers/Guideline.asp

HSL3880
Goldfinger SE.
A matter of influence.
N Engl J Med 1987 May 28;316(22):1408-9

HSL3871
Chotiner G.
Response
Journal of the American Academy of Dermatology 1987;17:866

HSL3903
Lexchin J.
Pharmaceutical promotion in Canada: convince them or confuse them.
Int J Health Serv 1987;17(1):77-89

HSL3915
Smith R.
In delicto flagrante
Medical Journal of Australia 1987;146:322-323

HSL3855
Doctors and the drug industry [Editor's response to 3rd letter (O'Dowd & Whibley)]
British Medical Journal 1986 Nov 1;293:1171

HSL3822
Smith R.
Doctors and the drug industry: too close for comfort.
Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):905-6

HSL3819
The relationship between physicians and the pharmaceutical industry: A report of the Royal College of Physicians.
J R Coll Physicians Lond 1986 Oct;20(4):235-42

HSL3931
Woods D.
Annual report to the readers
Canadian Medical Association Journal 1986 Jan 01;136(1):7

HSL3765
Blum AL, Chalmers TC, Deutsch E, Koch-weser J, Langman M, Rosen A, Tygstrup N, Zentgraf R.
Differing attitudes of industry and academia towards controlled clinical trials
European Journal of Clinical Investigation 1986;16:455-460

HSL3766
Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D.
University-industry research relationships in biotechnology: implications for the university
Science 1986;232:1361-1366

HSL3771
Guidelines for drug-company-supported CME
Canadian Medical Association Journal 1986;135:384A

HSL3828
Turner J.
Antibiotic conference cancelled for second time
Lancet 1986;1:333

HSL3832
Woods D.
PMAC to spend almost $1 million annually to reach “stakeholders”
Canadian Medical Association Journal 1986;134:1387, 1389

HSL3716
Jefferis JE.
The pharmaceutical industry and academic medicine: opportunities for physician collaboration.
Circulation 1985 Aug;72(2)

HSL3717
Kaplan NM.
Educating physicians in the use of pharmaceuticals.
Circulation 1985 Aug;72(2)

HSL3726
Miller K, Gouveia WA, Barza M, Bower K, Curtis L, Decker EL, Dorkin H, Estes M, Mackey W, Marchbein D, et al.
Undesirable marketing practices in the pharmaceutical industry.
N Engl J Med 1985 Jul 4;313(1):54

HSL3745
Gould D.
Funds that can foster suspicion
New Scientist 1985 Jun 13;106:30

HSL3767
Bowman MA.
The impact of the expanding supply of physicians on continuing medical education.
Mobius 1985 Apr;5(2):28-31

HSL3678
Donald AG.
Doctors and the pharmaceutical industry
Journal of the Royal College of General Practitioners 1984 May;34:301

HSL3615
Drug companies at a European congress
Lancet 1984;2:1031

HSL3623
Burley DM.
Doctors and the drug makers
Lancet 1984;2:404-405

HSL3640
Lexchin J.
Reader upset at CFPC’s involvement in prescribing survey
Canadian Family Physician 1984;30:1454

HSL3653
Rice DI.
The CFPC’s executive director replies
Canadian Family Physician 1984;30:1454-1455

HSL3589
Musher DM.
Antibiotics: the medium is the message.
Rev Infect Dis 1983 Jul-Aug;5(4):809-12

HSL3567
Drug companies and rheumatologists.
Br J Rheumatol. 1983 May 22;2:65-6

HSL3565
Doctors and the drug industry.
Br Med J (Clin Res Ed). 1983 Feb 19;286(6365):579-80

HSL3580
French TA.
Commercial approach of pharmaceutical industry
BMJ 1983;287:1632

HSL3552
Rochmis PG.
Seminars for physicians.
JAMA 1982 Oct 1;248(13):1580-1

HSL3533
Publicity and the public’s ‘right to know’
New Zealand Pharmacy 1982;2(6):19, 22

HSL3536
Bourbonniere C.
Ethical issues in sponsorship of CME
Canadian Medical Association Journal 1982;127:681

HSL3541
Gass DA.
Ethical issues in sponsorship of CME
Canadian Medical Association Journal 1982;127:681

HSL3547
Melville A, Johnson C.
Cured to death: the effects of prescription drugs
1982

HSL3557
Soffer A.
Hazards in publication of proceedings
Archives of Internal Medicine 1982;142:2074-2076

HSL3498
Christensen DB, Bush PJ.
Drug prescribing: patterns, problems and proposals.
Soc Sci Med [A] 1981 May;15(3)

HSL3466
Gray BV.
Trade displays at medical conferences
New Zealand Medical Journal 1980;92:401

HSL3472
Hymans R.
Trade displays at medical conferences
New Zealand Medical Journal 1980;92:329-330

HSL3477
Rheinstein P, Baum CS.
Labeling effectiveness and the health environment
1980;6:275-287

HSL2199
Kaplan NM.
Sounding Boards.The support of continuing medical education by pharmaceutical companies
N Engl J Med 1979 Jan 25;300(4):194-6

HSL3427
Hughes R, Brewin R.
The tranquilizing of America: pill popping and the American way of life
1979

HSL3428
Kaplan NM.
The support of continuing medical education by pharmaceutical companies
New England Journal of Medicine 1979;300:194-196

HSL3396
Kunin CM.
Clinical investigators and the pharmaceutical industry.
Ann Intern Med 1978 Nov;89(5)

HSL3386
Mergener M.
Detailmen: Their pharmaceutical knowledge and continuing education
Medical Marketing & Media 1977 Aug;12(8):26, 28-31

HSL2200
Rawlins MD.
The role of the pharmaceutical industry in postgraduate medical education.
Br J Clin Pharmacol 1977 Jun;4(3):257-9

HSL3346
Pharmaceutical industry is ‘reorienting’ its promotional activities
Canadian Family Physician 1977;23:262

HSL3296
Bates DG.
Reader objects to drug co. sponsorship of CME courses
Canadian Family Physician 1976;22:815

HSL3237
Cooperstock R.
Some factors involved in the increased prescribing of psychotropic drugs
Alcoholism and Drug Addiction Research Foundation of Ontario 1974

HSL2201
Goulston K.
Problems of postgraduate medical education.
Aust N Z J Med 1973 Jun;3(3):230-8

HSL3176
Barnhart , R .
The medical profession-drug industry alliance
New Physician 1970;20:164-171